The present study evaluated the potential of five generally recognized as safe (GRAS) or dietary compounds (α-mangostin, chrysin, ginger extract, pterostilbene and silybin) to inhibit oxidative (CYP) and conjugative (UGT) metabolism using pooled human intestinal and liver microsomes. Buprenorphine was chosen as the model substrate as it is extensively metabolized by CYPs to norbuprenorphine and by UGTs to buprenorphine glucuronide. Chrysin, ginger extract, α-mangostin, pterostilbene and silybin were tested for their inhibition of the formation of norbuprenorphine or buprenorphine glucuronide in both intestinal and liver microsomes. Pterostilbene was the most potent inhibitor of norbuprenorphine formation in both intestinal and liver microsomes, with IC 50 values of 1.3 and 0.8 μM, respectively, while α-mangostin and silybin most potently inhibited buprenorphine glucuronide formation. The equipotent combination of pterostilbene and ginger extract additively inhibited both pathways in intestinal microsomes. Since pterostilbene and ginger extract showed potent CYP and/or UGT inhibition of buprenorphine metabolism, their equipotent combination was tested to assess the presence of synergistic inhibition. However, because the combination showed additive inhibition, it was not used while performing IVIVE analysis. Based on quantitative in vitro-in vivo extrapolation, pterostilbene (21 mg oral dose) appeared to be most effective in improving the mean predicted F oral and AUC ∞ PO of buprenorphine from 3 ± 2% and 340 ± 330 ng*min/ml to 75 ± 8% and 36,000 ± 25,000 ng*min/ml, respectively. At a 10-fold lower dose of pterostilbene, the predicted buprenorphine F oral approximated sublingual bioavailability (~35%) and showed a 2-4 fold reduction in the variability around the predicted AUC ∞ PO of buprenorphine. These results demonstrate the feasibility of using various GRAS/dietary compounds to inhibit substantially the metabolism by CYP and UGT enzymes to achieve higher and less variable oral bioavailability. This inhibitor strategy may be useful for drugs suffering from low and variable oral bioavailability due to extensive presystemic oxidative and/or conjugative metabolism.
| INTRODUCTION
About 73% of the top 200 drugs are cleared by metabolism, of which the members of the cytochrome P450 (CYP) superfamily account for about 75%, with the CYP3A family being the major (46%) contributor (Wienkers & Heath, 2005) . Among the phase II metabolic pathways, UGTs play a crucial role in the metabolism of 20-30% of the currently marketed drugs (Stingl, Bartels, Viviani, Lehmann, & Brockmoller, 2014) and are responsible for 40-70% of all drugs metabolized through conjugation reactions (Bock, Lilienblum, Fischer, Schirmer, & BockHenning, 1987; Mulder, 1992; Radominska-Pandya, Czernik, Little, Battaglia, & Mackenzie, 1999; Tukey & Strassburg, 2000) . The UGTs occupy the second position after CYPs as the primary metabolic pathway, accounting for metabolism of 10% of the top 200 drugs (Wienkers & Heath, 2005; Williams et al., 2004) . Both enzymes can contribute significantly to the presystemic, i.e., gastrointestinal (GI) and hepatic metabolism of drugs, resulting in poor and highly variable oral bioavailability. Buprenorphine aptly exemplifies this observation as it suffers from poor and highly variable oral bioavailability (F oral ) -preventing its use after oral administration -due to extensive presystemic metabolism by CYPs (CYP3A4 -major, CYPs 2C8, 2C9 -minor) to form norbuprenorphine (Picard, Cresteil, Djebli, & Marquet, 2005) and UGTs (1A1, 1A3 and 2B7) to form buprenorphine glucuronide (Elkader & Sproule, 2005; Rouguieg, Picard, Sauvage, Gaulier, & Marquet, 2010) .
The primary oxidative metabolite norbuprenorphine, which is pharmacologically active with an estimated one-fiftieth of the analgesic potency of buprenorphine (Elkader & Sproule, 2005) , further undergoes glucuronidation (UGTs -1A1 and 1A3) to form norbuprenorphine glucuronide (Rouguieg et al., 2010) . Previous studies using pooled human intestinal (HIM) and liver (HLM) microsomes suggest oxidation to be the major metabolic pathway for buprenorphine in both intestine and liver (Cubitt, Houston, & Galetin, 2009; Kilford, Stringer, Sohal, Houston, & Galetin, 2009; Maharao, Joshi, & Gerk, 2017) .
Several generally recognized as safe (GRAS) compounds, dietary supplements and dietary constituents have been reported to enhance the bioavailability of orally administered drugs (Appiah-Opong, Commandeur, van Vugt-Lussenburg, & Vermeulen, 2007; Bhardwaj et al., 2002; Custodio, Wu, & Benet, 2008; Foti, Wahlstrom, & Wienkers, 2007; Gufford et al., 2014; Mandlekar, Hong, & Kong, 2006) . The proposed mechanisms responsible for this 'bioenhancement' include (i) improved GI solubility, (ii) delayed GI transit and emptying time, (iii) reduction in gastric acid secretion, (iv) increased intestinal permeation by modification of GI epithelial membranes, (v) increased intestinal blood perfusion, (vi) reduction in intestinal motility, (vii) inhibition of presystemic intestinal and hepatic metabolism, (vii) increased bile flow (Ajazuddin et al., 2014; Kesarwani, Gupta, & Mukerjee, 2013 ). The present discussion will focus on bioenhancement achieved through metabolic inhibition of CYP and UGT enzymes.
Our previous publication evaluated the potential of 27 compounds to inhibit the oxidative and conjugative metabolism of buprenorphine in pooled human intestinal and liver microsomes (Maharao et al., 2017) . Of these 27 compounds, chrysin, curcumin, ginger extract, 6-gingerol, hesperitin, α-mangostin, pterostilbene, quercetin, resveratrol and silybin appeared to be the most effective inhibitors of buprenorphine metabolism in intestinal and/or liver microsomes (Maharao et al., 2017) . From these 10 inhibitors, chrysin, ginger extract, α-mangostin, pterostilbene and silybin were further selected -based on their physicochemical characteristics, extent of CYP and UGT inhibition, expected Biopharmaceutical Classification System class, available oral PK data in animals and/or humans and maximum daily dose in humans. The present study aims to (a) determine the potency of inhibition (i.e. IC 50 ) of these five inhibitors towards the CYP and UGT metabolism of buprenorphine using pooled human intestinal and liver microsomes, (b) evaluate the effect of the inhibitor treatments on the mean and variability in the predicted F oral , AUC ∞ PO and total body clearance (CL B ) of buprenorphine using a sim- 
| Inhibition studies in pooled microsomes
The oxidative and conjugative metabolism of buprenorphine were studied individually in pooled human intestinal and liver microsomes as described previously (Maharao et al., 2017) . The results of the saturation assay from our previous publication are summarized in Table   S1 . The inhibitory potency, i.e. IC 50 , was determined by incubating buprenorphine (11 μM) with 0.1 mg/ml liver microsomes or 0.4 mg/ 
| Analysis of the combination of pterostilbene and ginger extract
The effect of the combination of pterostilbene and ginger extract on CYP and UGT pathways was studied individually in intestinal microsomes. These inhibitors were then combined in an equipotent manner, and a wide range of concentrations was studied to determine the inhibitory ratio (IR 50 ). IR 50 represents the concentration of the combination that produces 50% inhibition of metabolite formation. The nature of interaction in the combination was determined using curve shift analysis as described previously (Zhao, Wientjes, & Au, 2004) . 
| Analytical method
Buprenorphine and its metabolites buprenorphine glucuronide and norbuprenorphine were quantified using a previously validated method as described (Joshi, Maharao, & Gerk, 2016 were obtained for norbuprenorphine and buprenorphine from 25 to 4000 ng/ml and for the glucuronides from 100 to 4000 ng/ml.
Buprenorphine concentrations from the enzymatic assays that were outside the calibration curve of buprenorphine on the QDa mass detector were quantified by UV detection (Waters 2487) at 220 nm.
The same chromatographic system with the same column and mobile phase (Joshi et al., 2016) was also used for quantification of chrysin, α-mangostin, pterostilbene and silybin using UV spectrometric detection at 220 nm. Silybin, chrysin, pterostilbene and α- 3 | RESULTS
| Inhibition studies in pooled microsomes
The results of the saturation assay and the extrapolated F g and F h values of buprenorphine from our previous publication are reported in Supplemental Table S1 (Maharao et al., 2017) . The apparent IC 50 values of α-mangostin, chrysin, ginger extract, pterostilbene and silybin in HIM and HLM are as shown in Table 1 
| Inhibition by the equipotent combination of pterostilbene and ginger extract
The ratio of IC 50 s of pterostilbene and ginger extract for inhibition of norbuprenorphine formation appeared to be between 1:15 and 1:25.
However, those ratios could not be achieved in practice due to GI solubility issues. The highest achievable ratio of pterostilbene: ginger extract was 1:11, which is biased towards pterostilbene in its composition. For inhibition of buprenorphine glucuronide formation, the mean ratio of the IC 50 s of pterostilbene and ginger extract was 2:1.
Reproducible IC 50 and Hill slope values were achieved for the combination treatment towards inhibition of CYP and UGT metabolism of buprenorphine in pooled HIM with R 2 values ≥ 0.98 (Supplemental Table S2 and Figure 1 ). For both pathways, the combination curve 
| Effect of inhibitor treatments on predicted F oral , AUC ∞ PO and CL B of buprenorphine
A comprehensive validation of the predicted estimates of F oral , and AUC ∞ PO of buprenorphine (Supplemental Table S3 ) could not be performed because of a lack of thorough clinical studies evaluating the PK/systemic exposures after orally administered buprenorphine in humans. However, the predicted CL B (Supplemental Table S3 ) was in excellent agreement with the reported systemic clearance of buprenorphine after i.v. administration in humans (1043-1280 ml/ min) and hence could be validated (Elkader & Sproule, 2005) . The predicted F oral of buprenorphine was within the cut-off value (< 15%) alluded to by Jeffcoat et al. in the NIDA monograph (Jeffcoat et al., 1992) . As expected, the predicted AUC ∞ PO of buprenorphine (344 ± 327 ng*min/ml) was much lower and more variable than the reported AUC 0-72h = 1195 ± 760 ng*min/ml (Ciraulo et al., 2006) and AUC 0-∞ = 2231 ± 804 ng.min/ml (Buprenorphine 8 mg Sublingual
Tablets Under Fasting Conditions, 2010) after sublingual administration of a similar dose (10 mg p.o. vs 8 mg s.l.) of buprenorphine.
As stated in the Methods section, two scenarios comprising distinct % variability estimates in the intrinsic clearances were evaluated.
Based on the IVIVE study under both scenarios, buprenorphine is predicted to exhibit a poor and variable oral bioavailability of 3 ± 2%
(Supplemental Tables S1 and S3 ). Since the trend of results was similar between the two scenarios, only the results of scenario 1 will be discussed in detail (refer to Supplemental Table S1 for results of scenario 2). The CL B of buprenorphine was predicted to be~1050 to 1060 ml/min yielding a hepatic extraction ratio of 0.7 (assuming liver blood flow of 1500 ml/min (Pang & Rowland, 1977) ). The variability of 60% (case 1) and 81% (case 2) in the intestinal intrinsic clearances did not significantly affect the variability around the predicted means of F oral , AUC ∞ PO and CL B of buprenorphine (Supplemental Table S3 ).
Hence, a variability of 60% in CL int(GW) was used for all further extrapolations in scenario 1.
We first considered the effects of inhibitor treatments on the predicted means for all PK endpoints/exposure metric after a 10 mg dose of p.o. buprenorphine, which appeared to be similar under the conditions of scenarios 1 and 2. All inhibitor treatments except pterostilbene and silybin (using predicted solubility) failed to achieve and AUC ∞ PO of buprenorphine, respectively, and only a minor, 2-fold reduction in the mean CL B of buprenorphine; based on the extrapolations made using its predicted maximal solubility.
Next, we considered the effect of inhibitors on the variability associated with the mean. The variability around the mean PK endpoints/exposure metric was higher under scenario 1 than under scenario 2 due to the larger % variability in the intrinsic clearances in 
| Sensitivity analysis
Under both scenarios 1 and 2, CL int(GW,CYP) was predicted to be the 
| DISCUSSION
Buprenorphine is an example of such a compound that is oxidized (by CYP3A4, 2C8 and 2C9) to form norbuprenorphine as well as glucuronidated (by UGT1A1, 1A3 and 2B7) to form buprenorphine glucuronide (Cubitt et al., 2009; Elkader & Sproule, 2005; Kilford et al., 2009; Picard et al., 2005; Rouguieg et al., 2010) . The contribution of CYP and UGT pathways to the presystemic intestinal and hepatic metabolism of buprenorphine was studied in our previous publication. In both organs, oxidative metabolism was dominant over glucuronidation and accounted for 86% (intestine) and 79% (liver) of the overall first-pass metabolism of buprenorphine (Supplemental Table S1 ). The %F g and %F h values extrapolated from in vitro data using the well-stirred model were found to be 9% and 29%, emphasizing the role of the gut wall in lowering the oral bioavailability of reported to be about 5% of UGT2B7 suggesting only a minor contribution of UGT2B17 towards the conjugation of buprenorphine (Beaulieu, Levesque, Hum, & Belanger, 1996; Ohno & Nakajin, 2009 ). There is minimal to no expression of UGT1A3 in the intestine (Harbourt et al., 2012; Ohno & Nakajin, 2009; Seo et al., 2014) . Thus, it is logical to expect a higher contribution from UGT1A1, 2B7 and possibly UGT2B17 in the intestinal conjugation of buprenorphine.
Thus, if silybin inhibits only UGT1A1 and 2B7 with minimal to no effect on UGT1A3, then this could possibly explain the complete inhi- Table S2 ). No significant shift was observed for the combination curve with respect to the individual inhibitor curves indicating additive interactions in the combination (Figure 1) . Similarly, the equipotent combination of pterostilbene and ginger extract (2:1) showed additive interactions towards the inhibition of buprenorphine glucuronide formation in intestinal microsomes (Figure 1 ). This finding suggests that pterostilbene and ginger extract are likely to act competitively with Within the past few decades numerous studies emphasizing the contribution of the intestine to CYP3A4 metabolism have been published (Barter et al., 2010; Cubitt, Houston, & Galetin, 2011 , Cubitt, Yeo, et al., 2011 Darnell, Ulvestad, Ellis, Weidolf, & Andersson, 2012; Gertz, Harrison, Houston, & Galetin, 2010; Hallifax, Foster, & Houston, 2010; Houston & Galetin, 2008; Howgate, Rowland Yeo, Proctor, Tucker, & Rostami-Hodjegan, 2006; Kato, Chiba, Ito, Koue, & Sugiyama, 2010; Shiran et al., 2006; Wienkers & Heath, 2005) .
Drugs metabolized by CYP3A4 have been reported to exhibit a high degree of interindividual variability (Barter et al., 2010; Cubitt, Houston, & Galetin, 2011 , Cubitt, Yeo, et al., 2011 Darnell et al., 2012; Gertz et al., 2010; Hallifax et al., 2010; Houston & Galetin, 2008 to be the high variability in the metabolic activity of hepatic and intestinal CYP3A4 (Barter et al., 2010; Cubitt, Houston, & Galetin, 2011 , Cubitt, Yeo, et al., 2011 Darnell et al., 2012; Gertz et al., 2010; Hallifax et al., 2010; Houston & Galetin, 2008; Howgate et al., 2006; Kato et al., 2010; Shiran et al., 2006; Wienkers & Heath, 2005) . Numerous sources of variability have been proposed and studied such as genetic polymorphism, epigenetic factors, non-genetic factors such as age, gender, body weight, liver blood flow, expression of drug metabolizing enzymes and transporters, disease states, enzyme induction or inhibition (Zanger & Schwab, 2013 ).
Cubitt et al. conducted a study to estimate the interindividual variability in hepatic CYP3A4 abundance (using three CYP3A substrates, i.e. alprazolam, triazolam, and midazolam) to improve the estimation of variability in the predicted in vivo clearance (Cubitt, Yeo, et al., 2011) . The variability in CYP3A4 abundance was studied using 52 human livers, and the interindividual variability in abundance was estimated to be about 41% (Cubitt, Yeo, et al., 2011). Kato et al. performed an in silico study to predict the factors contributing to the FIGURE 2 Continued interindividual variability in PK parameters (AUC, total and oral clearance, intestinal and hepatic extraction) in humans. They identified the hepatic CYP3A4 content as the most sensitive parameter affecting the variability in AUC dose of the test substrate (Kato et al., 2010) . This study reported %CV of 33% and 81% for hepatic CYP3A4 content and intrinsic intestinal clearance corrected for permeability, respectively (Kato et al., 2010) . Another study conducted by Paine et al. using six human intestines reported 60% variability in the intestinal CYP3A4 content (Paine et al., 1997) . However, the 60% and 81% variability reported in both the studies likely accounts for both experimental and true interindividual variability (Cubitt, Yeo, et al., 2011) . In the absence of inhibitors, a 10 mg dose of buprenorphine was predicted to exhibit poor F oral (< 5%) and low AUC ∞ PO with 46% to 66% and 50% to 95% variability, respectively, as well as a large CL B (1050 to 1060 ml/min) in both scenarios -consistent with the high presystemic extraction by GI and hepatic CYP and UGT metabolism as well as high systemic/hepatic extraction via CYP and UGT metabo- showing a higher contribution of oxidation (6-fold in the intestine and 4-fold in the liver) than glucuronidation to the overall metabolism of buprenorphine (Maharao et al., 2017 Of all the inhibitor treatments, pterostilbene is expected to have the highest portal vein concentration (portal vein concentration) of 40.6 μM -predicted using the lowest reported oral bioavailability of 12.5% (Lin, Yue, & Ho, 2009) . To assess the effect of a lower portal vein concentration of pterostilbene, a dose-dependency simulation study was performed using five additional, lower doses of pterostilbene ( Figure 3) . A ten-fold lower pterostilbene dose (i.e.
2.1 mg) that could still achieve the predicted F oral similar to the reported F sublingual of buprenorphine (~35%) was chosen for further analysis. Published studies report a wide variability in F oral of pterostilbene in rats ranging from 12.5% to 80% (Azzolini et al., 2014; Bethune, Schultheiss, & Henck, 2011; Kapetanovic, Muzzio, Huang, Thompson, & McCormick, 2011; Lin et al., 2009 ), depending in part on the dose administered and the formulation. Hence, in an attempt to capture this wide range, an additional variability of 60% was introduced in the portal vein concentration, and the effect of this lower dose on PK endpoints/exposure metrics for buprenorphine was investigated. As shown in Table 2 , the variability in AUC ∞ PO of buprenorphine was reduced by almost 50% in scenario 1 (from 95% to 49%). Increasing the variability in the portal vein concentration from 20% to 60% resulted only in a minor increase in the variability (Table 2) . Thus, a lower dose of pterostilbene was more effective in reducing the variability in the PK endpoints/exposure metrics for buprenorphine (10 mg p.o.), while achieving on average F oral values similar to the sublingual availability of currently marketed buprenorphine formulations (8 mg s.l.). In addition, there was also a significant improvement in the predicted mean AUC ∞ PO and a modest reduction in the variability associated with the mean AUC ∞ PO of buprenorphine under both scenarios making pterostilbene the most favored candidate of all the inhibitors.
Significant research has been conducted on the use of various herbal compounds as bio-enhancers acting via inhibition of the most prevalent drug metabolizing enzymes such as CYP (especially CYP3A4) and UGTs (Appiah-Opong et al., 2007; Basheer & Kerem, 2015; Bhardwaj et al., 2002; Cubitt, Yeo, et al., 2011; Custodio et al., 2008; Dudhatra et al., 2012; Foti et al., 2007; Gufford et al., 2014; Kato et al., 2010; Mandlekar et al., 2006; Paine et al., 1997; Peters, Schroeder, Giri, & Dolgos, 2012; Thummel, 2007) . Their application to improve the oral bioavailability of therapeutic agents has also been proposed, studied using in vitro systems, and modeled using diverse in silico systems and PBPK models Mandlekar et al., 2006; Paine et al., 1997; Peters et al., 2012; Shen et al., 1997; Thummel, 2007) . However, there is a lack of combinatorial studies such as this one, which investigated the effect of such herbal/dietary agents not only to improve the average oral bioavailability of a drug, but also to reduce the variability in its systemic exposures after associated oral administration, which would enable further development of such a bioenhancement strategy rather than just increasing p.o. doses and/or improving GI solubility/permeability.
| CONCLUSION
The overall results demonstrate the feasibility of the proposed approach of co-administering GRAS inhibitors such as pterostilbene with buprenorphine to inhibit its oxidative and conjugative metabolism and to achieve a sufficiently high F oral and AUC ∞ PO to produce its intended pharmacological effects. These results support the potential of developing an efficacious oral formulation of buprenorphine with greater patient compliance to serve as a better alternative to sublingual buprenorphine. The GRAS inhibitor strategy has promising applicability to a variety of drugs such as buprenorphine that suffer from low and variable oral bioavailability due to extensive presystemic metabolism.
